OKT3-associated adverse reactions: Mechanistic basis and therapeutic options

Manikkam Suthanthiran, M. Fotino, R. R. Riggio, J. S. Cheigh, K. H. Stenzel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

OKT3, a prototypic monoclonal antibody directed at the lineage-specific CD3 antigen expressed on mature T cells, is an effective immunosuppressant in organ graft recipients. Unfortunately, a variety of adverse reactions are observed following the first and second doses of OKT3. In a series of experiments designed to examine the signaling repertoire of OKT3, it was found that (1) OKT3 is an effective substitute for the alloantigen stimulus in the activation of antigen-specific memory T cells; (2) OKT3 is a potent inducer of cytolytic activity (secondary cytotoxic T-cell activity as well as natural killer-cell activity); (3) OKT3 is also an inducer of interleukin-2 and interferon gamma production; and (4) of the immunosuppressants currently in clinical use, cyclosporine >methylprednisolone>6-mercaptopurine (an in vivo cleavage product of azathioprine) in curtailing T-cell activation with OKT3. Collectively, these observations suggest a potential mechanistic basis for the adverse reactions associated with OKT3 and provide experimental support for therapeutic strategies that include the use of cyclosporine and/or methylprednisolone before OKT3 administration.

Original languageEnglish
Pages (from-to)39-44
Number of pages6
JournalAmerican Journal of Kidney Diseases
Volume14
Issue number5 SUPPL. 2
Publication statusPublished - 1 Jan 1989
Externally publishedYes

Fingerprint

Muromonab-CD3
T-Lymphocytes
Therapeutics
Methylprednisolone
Immunosuppressive Agents
Cyclosporine
CD3 Antigens
6-Mercaptopurine
Isoantigens
Azathioprine
Natural Killer Cells
Interferon-gamma
Interleukin-2
Monoclonal Antibodies
Transplants
Antigens

ASJC Scopus subject areas

  • Nephrology

Cite this

Suthanthiran, M., Fotino, M., Riggio, R. R., Cheigh, J. S., & Stenzel, K. H. (1989). OKT3-associated adverse reactions: Mechanistic basis and therapeutic options. American Journal of Kidney Diseases, 14(5 SUPPL. 2), 39-44.

OKT3-associated adverse reactions : Mechanistic basis and therapeutic options. / Suthanthiran, Manikkam; Fotino, M.; Riggio, R. R.; Cheigh, J. S.; Stenzel, K. H.

In: American Journal of Kidney Diseases, Vol. 14, No. 5 SUPPL. 2, 01.01.1989, p. 39-44.

Research output: Contribution to journalArticle

Suthanthiran, M, Fotino, M, Riggio, RR, Cheigh, JS & Stenzel, KH 1989, 'OKT3-associated adverse reactions: Mechanistic basis and therapeutic options', American Journal of Kidney Diseases, vol. 14, no. 5 SUPPL. 2, pp. 39-44.
Suthanthiran, Manikkam ; Fotino, M. ; Riggio, R. R. ; Cheigh, J. S. ; Stenzel, K. H. / OKT3-associated adverse reactions : Mechanistic basis and therapeutic options. In: American Journal of Kidney Diseases. 1989 ; Vol. 14, No. 5 SUPPL. 2. pp. 39-44.
@article{74642a4fccb34abf86f75663eee997c1,
title = "OKT3-associated adverse reactions: Mechanistic basis and therapeutic options",
abstract = "OKT3, a prototypic monoclonal antibody directed at the lineage-specific CD3 antigen expressed on mature T cells, is an effective immunosuppressant in organ graft recipients. Unfortunately, a variety of adverse reactions are observed following the first and second doses of OKT3. In a series of experiments designed to examine the signaling repertoire of OKT3, it was found that (1) OKT3 is an effective substitute for the alloantigen stimulus in the activation of antigen-specific memory T cells; (2) OKT3 is a potent inducer of cytolytic activity (secondary cytotoxic T-cell activity as well as natural killer-cell activity); (3) OKT3 is also an inducer of interleukin-2 and interferon gamma production; and (4) of the immunosuppressants currently in clinical use, cyclosporine >methylprednisolone>6-mercaptopurine (an in vivo cleavage product of azathioprine) in curtailing T-cell activation with OKT3. Collectively, these observations suggest a potential mechanistic basis for the adverse reactions associated with OKT3 and provide experimental support for therapeutic strategies that include the use of cyclosporine and/or methylprednisolone before OKT3 administration.",
author = "Manikkam Suthanthiran and M. Fotino and Riggio, {R. R.} and Cheigh, {J. S.} and Stenzel, {K. H.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "14",
pages = "39--44",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 2",

}

TY - JOUR

T1 - OKT3-associated adverse reactions

T2 - Mechanistic basis and therapeutic options

AU - Suthanthiran, Manikkam

AU - Fotino, M.

AU - Riggio, R. R.

AU - Cheigh, J. S.

AU - Stenzel, K. H.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - OKT3, a prototypic monoclonal antibody directed at the lineage-specific CD3 antigen expressed on mature T cells, is an effective immunosuppressant in organ graft recipients. Unfortunately, a variety of adverse reactions are observed following the first and second doses of OKT3. In a series of experiments designed to examine the signaling repertoire of OKT3, it was found that (1) OKT3 is an effective substitute for the alloantigen stimulus in the activation of antigen-specific memory T cells; (2) OKT3 is a potent inducer of cytolytic activity (secondary cytotoxic T-cell activity as well as natural killer-cell activity); (3) OKT3 is also an inducer of interleukin-2 and interferon gamma production; and (4) of the immunosuppressants currently in clinical use, cyclosporine >methylprednisolone>6-mercaptopurine (an in vivo cleavage product of azathioprine) in curtailing T-cell activation with OKT3. Collectively, these observations suggest a potential mechanistic basis for the adverse reactions associated with OKT3 and provide experimental support for therapeutic strategies that include the use of cyclosporine and/or methylprednisolone before OKT3 administration.

AB - OKT3, a prototypic monoclonal antibody directed at the lineage-specific CD3 antigen expressed on mature T cells, is an effective immunosuppressant in organ graft recipients. Unfortunately, a variety of adverse reactions are observed following the first and second doses of OKT3. In a series of experiments designed to examine the signaling repertoire of OKT3, it was found that (1) OKT3 is an effective substitute for the alloantigen stimulus in the activation of antigen-specific memory T cells; (2) OKT3 is a potent inducer of cytolytic activity (secondary cytotoxic T-cell activity as well as natural killer-cell activity); (3) OKT3 is also an inducer of interleukin-2 and interferon gamma production; and (4) of the immunosuppressants currently in clinical use, cyclosporine >methylprednisolone>6-mercaptopurine (an in vivo cleavage product of azathioprine) in curtailing T-cell activation with OKT3. Collectively, these observations suggest a potential mechanistic basis for the adverse reactions associated with OKT3 and provide experimental support for therapeutic strategies that include the use of cyclosporine and/or methylprednisolone before OKT3 administration.

UR - http://www.scopus.com/inward/record.url?scp=0024306983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024306983&partnerID=8YFLogxK

M3 - Article

C2 - 2530898

AN - SCOPUS:0024306983

VL - 14

SP - 39

EP - 44

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5 SUPPL. 2

ER -